Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").
ESS, previously known as PermaDerm® is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015.
For further information, please visit www.Amarantus.com, or connect with the company in Facebook, Twitter, LinkedIn & Google+
|PRESS RELEASES & NEWS ARTICLES |
Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
March 26, 2015
Amarantus Shareholder Update: Fundamental Progress on the Pipeline and Strategy Continues
Thursday, March 26th, 2015
Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015
March 23, 2015
A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason Napodano - Wednesday, March 4, 2015
Large Pharmaceuticals and Biotech Startups Partnering To Develop Alzheimer’s Treatments
February 26, 2015
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Feb. 23, 2015
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Feb. 18, 2015
New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
Feb. 10, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia - The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
Amarantus Creates Alzheimer`s Disease Diagnostics Scientific Advisory Board
FEBRUARY 3RD, 2015
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015
Developing an Accurate Test for Multiple Sclerosis Mar 5, 2014
December 12, 2014
SNNLive - Amarantus BioScience Holdings, Inc.
Oct. 19, 2014
Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
c/o ICS Corporate Services SA
29 quai du Mont Blanc
Phone: (408) 737-2734
Fax: (408) 852-4427
| |Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
Gerald's email address
| |“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”
| Gerald E. Commissiong - We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value. |
Gerald E. Commissiong, President & CEO, will be presenting at the Neurotech Investing and Partnering Conference being held April 7-8, 2015 at the Hotel Nikko in San Francisco, CA. Mr. Commissiong will discuss the Company's proprietary Alzheimer's blood diagnostic LymPro Test®and the strategic plans for Amarantus Diagnostics on Tuesday, April 7, 2015, from 10:30-11:30 a.m. Pacific Daylight